Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMNi-BiOTiC STRESS Repair
- Development stage
- Unknown
- Lead developer
- Institut AllergoSan
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
OMNi-BiOTiC STRESS Repair is a multispecies probiotic dietary supplement developed by Institut AllergoSan. It contains nine scientifically tested bacterial strains, including *Lactobacillus casei* W56, *Lactococcus lactis* W19, *Lactobacillus acidophilus* W22, *Bifidobacterium lactis* W52, *Lactobacillus paracasei* W20, *Lactobacillus plantarum* W62, *Bifidobacterium lactis* W51, *Bifidobacterium bifidum* W23, and *Lactobacillus salivarius* W24. The formulation is designed to target the gut-brain axis and support the intestinal microbiome, particularly during periods of stress. It aims to improve intestinal barrier function (reducing "leaky gut"), modulate immune activation, and influence tryptophan metabolism. Clinical research has explored its effects on biomarkers of inflammation and neurodegeneration in conditions such as Alzheimer's disease and liver cirrhosis, as well as its impact on mood and sleep quality.
- Brand names
- OMNi-BiOTiC STRESS Repair
- Other names
- Omni-Biotic Stress Release ProbioticOmnibiotic Stress Repair
02
Targets
ZonulinIDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on OMNi-BiOTiC STRESS Repair.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMNi-BiOTiC STRESS Repair.